Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment

Current Diabetes Reports

Volumn 8, Issue 1, 2008, Pages 12-19

  Perkins, Jennifer M ^b   Davis, Stephen N ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; METFORMIN; PLACEBO; RIMONABANT; SULFONYLUREA DERIVATIVE;

ANXIETY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG EFFICACY; DYSLIPIDEMIA; ENERGY METABOLISM; FEEDING BEHAVIOR; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; INSOMNIA; INSULIN SENSITIVITY; LIPOPROTEIN METABOLISM; LOW CALORY DIET; METABOLIC INHIBITION; METABOLIC REGULATION; METABOLIC SYNDROME X; MUSCLE METABOLISM; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT REDUCTION;

CLINICAL TRIALS AS TOPIC; ENDOCANNABINOIDS; ENERGY METABOLISM; FEEDING BEHAVIOR; HUMANS; METABOLIC SYNDROME X; PIPERIDINES; PYRAZOLES;

EID: 40749085693     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0004-3     Document Type: Review

References (48)

1. Matias I, Gonthier MP, Orlando P, et al.: Regulation, function and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006, 91:3171-3180.
2. Gaoni Y, Mechoulam R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646-1647.
3. Matsuda LA, Lolait SJ, Brownstein MJ, et al.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
4. Howlett AC: The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002, 68:619-631.
5. Ameri A: The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-318.
6. Howlett AC, Barth F, Bonner TI, et al.: International Union of Pharmacology. XXVII. Classification of cannabinoids receptors. Pharmacol Rev 2002, 54:161-202.
7. Okamoto Y, Morishita J, Tsuboi K, et al.: Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004, 279:5298-5305.
8. Piomelli D: The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 2003, 4:873-884.
9. Engeli S, Bohnke J, Feldpausch M, et al.: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
10. Kirkham TC, Williams CM, Fezza F, et al.: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002, 136:550-557.
11. Sharkey KA, Pittman QJ: Central and peripheral signaling mechanisms involved in endocannabinoid regulation of feeding: a perspective on the munchies. Sci STKE 2005, pe15.
12. Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
13. Di Marzo V, Goparaju SK, Wang L, et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
14. Hanus L, Avraham Y, Ben-Shushan D, et al.: Short term fasting and prolonged semistarvation have opposite effects on 2-AG levels in the mouse brain. Brain Res 2003, 983:144-151.
15. Hao S, Avaraham Y, Mechoulam R, et al.: Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000, 392:147-156.
16. Matias I, Di Marzo V: Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2006, 18:27-37.
17. Ravinet Trillou C, Delgorge C, et al.: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004, 28:640-648.
18. Bensaid M, Gary-Bobo M, Esclangon A, et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
19. Cota D, Marsiacano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
20. Gary-Bobo M, Elachouri G, Scatton B, et al.: The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006, 69:471-478.
21. Bluher M, Engeli S, Kloting N, et al.: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053-3060.
22. Engeli S, Fledpausch M, Gorzelniak K, et al.: Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003, 52:942-947.
23. Woods SC: Role for the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med 2007, 120:S19-S25.
24. Osei-Hyiaman D, DePetrillo M, Pacher P, et al.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
25. Medina J, Fernández-Salazar L, García-Buey L, Moreno-Otero R: Approach to the pathogenesis and treatment of nonalcobolic steatohepatitis. Diabetes Care 2004, 27:2057-2066.
26. Teixeira-Clerc F, Julien B, Grenard P, et al.: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006, 12:671-676.
27. Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of CB1 receptor antagonist SR141716 on oxygen consumption and solens muscle glucose uptake in lep(ob)/lep(ob) mice. Int J Obes Relat Metab Disord 2005, 29:183-187.
28. Pagotto U, Marsicano G, Cota D, et al.: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006, 27:73-100.
29. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, et al.: Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta cell. Cell Calcium 2005, 39:155-162.
30. Bermudez-Siva FJ, Serrano A, Diaz-Molina F, et al.: Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006, 531:282-284.
31. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, et al.: Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007, 565:207-211.
32. Gomez R, Navarro M, Ferrer B, et al.: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002, 22:9612-9617.
33. Coutts AA, Izzo AA: The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 2004, 4:572-579.
34. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heat, Lung and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
35. American Heart Association: Heart disease and stroke statistics-2007 Update-At-a-Glance. Available at http://www.americanheart.org/ downloadable/heart/1166711577754HS_StatsInsideText.pdf. Accessed October 25, 2007.
36. National diabetes information clearinghouse: National diabetes statistics. Available at http//diabetes.niddk.nih.gov/dmpubs/ statistics/. Accessed August 10, 2007.
37. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004, 27:2444-2449.
38. Harrold JA, Elliott JC, King PJ, et al.: Down-regulation of cannabinoid-1 (CB1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002, 952:232-238.
39. Maccarrone M, Fride E, Bisogno T, et al.: Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod 2005, 11:21-28.
40. Cote M, Matias I, Lemieux I, et al.: Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors. Int J Obes 2007, 31:692-699.
41. Rinaldi-Carmona M, Barth F, Heaulme M, et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350:240-244.
42. Ravinet-Trillou C, Arnone M, Delgorge C, et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.
43. Jbilo O, Ravinet-Trillou C, Arnone M, et al.: The CB1 receptor antagonist rimonabant reverses the diet induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005, 19:1567-1569.
44. Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
45. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid receptor 1 blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-765.
46. Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
47. Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of Rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006, 368:1660-1672.
48. Iranmanesh A, Rosenstock J, Hollander P: SERENADE: Rimonabant monotherapy for treatment of multiple cardio-metabolic risk factors in treatment-naive patients with type 2 diabetes. Diabet Med 2006, 23(suppl 4):230A (637b).